Immunocore Holdings PLC
NASDAQ:IMCR

Watchlist Manager
Immunocore Holdings PLC Logo
Immunocore Holdings PLC
NASDAQ:IMCR
Watchlist
Price: 28.66 USD 1.85% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Immunocore Holdings PLC?
Write Note

Immunocore Holdings PLC
Investor Relations

Immunocore Holdings PLC stands as a pioneering force in the field of immunotherapy, leveraging its proprietary T-cell receptor (TCR) technology to transform the treatment landscape for various severe diseases. Rooted in cutting-edge science, the British biotech firm develops novel therapeutic agents targeting cancer, infectious diseases, and autoimmune conditions. Its leading platform technology, known as ImmTACs (Immune Mobilizing Monoclonal TCRs Against Cancer), ingeniously redirects T-cells—an integral component of the immune system—to recognize and obliterate cancerous cells in a highly targeted manner. By focusing on ultra-specific peptide-major histocompatibility complex (pMHC) targets, Immunocore meticulously designs its therapies to minimize off-target effects and maximize efficacy in tackling conditions that have eluded traditional treatment methods.

Financially, Immunocore operates through a strategic blend of commercial and collaborative partnerships, alongside its independent pipeline advancements. It generates revenue by licensing its innovative technology to larger pharmaceutical entities that seek to add cutting-edge biologics to their portfolios. Additionally, milestone and royalty payments from collaborative research initiatives contribute significantly to its financial foundation. These partnerships not only bolster Immunocore's revenue streams but also accelerate its research and development efforts, enabling a faster path to market for its groundbreaking treatments. As a result, the company stands at the confluence of science and commerce, channeling its unique TCR technology to make meaningful strides in medical innovation and patient care.

Show more

Earnings Calls

Show Transcript
Previous
Next
Loading

Management

Dr. Bahija Jallal Ph.D.
CEO & Executive Director
No Bio Available
Mr. Brian R. Di Donato M.B.A.
Executive VP, CFO & Strategy
No Bio Available
Ms. Tina St. Leger
Chief Human Resources Officer
No Bio Available
Dr. David Berman M.D., Ph.D.
Executive Vice President of Research & Development
No Bio Available
Mr. John Goll III
SVP, Finance & Chief Accounting Officer
No Bio Available
Ms. Annelise Vuidepot Ph.D.
Senior VP, CTO and Research & UK Site Lead
No Bio Available
Mr. Sean D. Buckley
VP & Chief Information Officer
No Bio Available
Clayton Robertson
Head of Investor Relations
No Bio Available
Ms. Lily Margaret Hepworth
Senior VP, General Counsel & Company Secretary
No Bio Available
Ms. Elizabeth Varki Jobes Esq., J.D.
Chief Compliance Officer
No Bio Available

Contacts

Address
OXFORDSHIRE
Abingdon
90 Park Drive, Milton Park, Abingdon
Contacts
+441235438600.0
www.immunocore.com